home > news > detailed info

Data custodianship of connected devices, environmental impact and adherence technologies highlighted at Pharmapack Europe 2020


Global biologics markets, delivery device innovation and smart packaging ‘unpacking’ new growth opportunities for pharma

Paris, 19th February 2020: Improving adherence to medication via smarter, patient-centric pharmaceutical packaging and extracting further value from existing medicines and delivery devices are two of the latest key strategies aimed at reducing waste and protecting the bottom line, according to experts at the recent Pharmapack Europe (#pharmapackeu). The event is widely seen as an excellent yardstick of the industry’s prospects for the year ahead. Encouragingly, the event played host a record 411 exhibiting companies, 5366 attendees and 325 delegates.

Europe’s leading pharmaceutical packaging and drug delivery event – which took place at the Paris Expo, Porte de Versailles, February 5-6 – featured many innovations as well as novel drug delivery solutions, with ‘waste management’, “connectivity” and “patient centricity” being some the key themes throughout this year’s edition.

A who’s who of pharma packaging and drug device innovators exhibited from Aptar, SHL, Stevanato Group and BD to Nemera and West Pharmaceutical Services – with several major new technologies and partnerships announced. But some of the most promising innovations were presented by emerging companies in the Start-up hub – with technologies featured from AI development platforms through miniaturized/non-intrusive sensors, to vial/ampule combination devices ad smart packaging.

The conference played host to four themed content sessions, while the learning labs and several educational and interactive workshops explored major industry changes that lie ahead. Aurelio Arias, Engagement Manager at IQVIA suggested during his session that ‘the future of Value-Added Medicines is not just driven by deeper Insights and data capture but will also see gamification transforming engagement of therapies’. Arias added that ‘while patients are concerned about the security and the custodianship of their data’, they are still actively using connected devices. As a result, the natural evolution of this trend could be that healthcare companies will increasingly incentivise better compliance through gamification.

Yet one area that connected devices perhaps lag begin other areas of pharma packaging and devices is in environmental impact. Gregor Anderson, Managing Director at Pharmacentric solutions believes that the industry still has a long way to go when it comes to the sustainability of connected devices, commenting on ‘the duality of connected devices’. On one hand, it is an exciting field of new possibilities, but unfortunately on the other, we have not yet ‘fully married them with our sustainability goals’. He believes that is the next evolution for the industry in the year ahead, as more devices and technologies are now moving into commercial applications

In the ‘Challenges in drug delivery for biologics’ session, experts agreed that combining biologic drug and device development, while meeting regulatory standards is a significant learning curve for the industry. Overall, drug delivery was seen as increasingly integral to the growth of the biologics market, with patient centricity an essential component in adherence. In the short term, this is projected to push manufacturers to provide better devices – that ease the patient experience. But in the long term, experts postulated connected devices will play a major role in the advancement of the biologics industry – with increasingly levels of vital data on how devices are used post launch.

In the ‘New horizons in innovation’ session, Marc Rohrschneider, Head New Technologies, Device Development and Commercialisation at Novartis AG predicted that with pharma now having access to technology to connect boxes, vials and devices to networks, the next decade is not about the technology challenges. But will instead explore how the industry safeguards data, and ultimately, who is its custodian. Blockchain is another industry buzzword of the last year, but experts at Pharmapack point to the improved accountability it could provide in pharma supply as its most immediate use, rather than in securing patient data. “You should think of it as the most secure audit trail you can have. Immutable, temporal and despite what many have said, scalable” commented Jason Lacombe, Chief Executive Officer, Veratrak. But the key to delivering on its potential is for pharma and tech communities to work closer together to deliver over the hype.

Silvia Forroova, Brand Director at Pharmapack Europe commented, “In the last few years, as our Pharmapack agenda is testament to, we have seen the rise of truly patient centric delivery forms, increasingly smart and child safe packaging, and a growing awareness of the vital role we can play in bringing about a more environmentally friendly industry. But what we are also seeing is that by bringing different groups together we are reinventing the art of the possible. It’s one of the greatest strengths of Pharmapack that we provide a platform to help build networks and communities, share learning and celebrate new innovations. Our experience of this event in 2020 is that the industry looks well set for growth in the year ahead and we can expect to see more collaborations in an age when the delivery of products is changing quickly. This is great news for drug delivery and packaging companies, but even better news for patients.”

Pharmapack Europe 2021 return to the Paris Expo, Porte De Versailles in Paris between the 27 & 28 January and is the leading hub for stakeholders across all parts of the pharmaceutical packaging and drug delivery supply chain.

To exhibit at next year’s show, please visit:
phone +31(0)20 708 1637
email Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
Print this page
Send to a friend
News and Press Releases

ERT Offers First Patient-Administered ECG Assessment for Continuation of Clinical Trials during COVID-19

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a first-of-its-kind partnership with AliveCor, the leader in AI-based, personal ECG technology. The partnership enables ERT to capture digital cardiac safety data with KardiaMobile 6L, the only FDA-cleared personal ECG for patient-administered 6-lead data collection.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement